Condition: Crohn's Disease · Sponsor: Takeda
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China. Participants will receive an injection of Vedolizumab 300 mg at scheduled weeks 0, 2, and 6, and starting at week 14, every 8 weeks over 58 weeks or starting at week 18, every 4 weeks over 54 weeks. There will be up to 20 study visits over 58 weeks to complete assessments.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| The Second Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Yijishan Hospital of Wannan Medical College | Wuhu, Anhui, China | Recruiting |
| Peking University First Hospital - Changqiao Campus | Beijing, Beijing Municipality, China | Completed |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| Lanzhou University Second Hospital | Lanzhou, Gansu, China | Recruiting |
| The First People's Hospital of Foshan | Foshan, Guangdong, China | Recruiting |
| The First Affiliated Hospital, Sun Yat-sen University - Main | Guangzhou, Guangdong, China | Recruiting |
| Guangzhou First People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| The Third Affiliated Hospital, Sun Yat-Sen University | Guangzhou, Guangdong, China | Completed |
| The Sixth Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05837897